|
FY2025
12 months to Dec 31, 2025
|
|
|---|---|
| Revenues | |
| License Revenue | |
| Research and Development Services Revenue | |
| Total revenues | |
| Operating expenses: | |
| Research and development | |
| Acquisition of in-process research and development | |
| General and administrative | |
| Total operating expenses | |
| Loss from operations | |
| Other income (expense), net: | |
| Interest income | |
| Interest expense | |
| Change in fair value of assets and liabilities, net | |
| Gain on other investments | |
| Gain on consolidation of Beckley Psytech | |
| Change in fair value of digital assets, net | |
| Foreign exchange loss, net | |
| Other income (expense), net | |
| Net loss before income taxes | |
| Benefit from (provision for) income taxes | |
| Losses from investments in equity method investees, net of tax | |
| Net loss | |
| Net loss attributable to noncontrolling interests | |
| Net loss attributable to ATAI Life Sciences N.V. stockholders | |
| Net loss per share attributable to AtaiBeckley Inc. shareholders - basic | |
| Net loss per share attributable to AtaiBeckley Inc. shareholders - diluted | |
| Weighted average common stock outstanding attributable to AtaiBeckley Inc. Stockholders - basic | |
| Weighted average common stock outstanding attributable to AtaiBeckley Inc. Stockholders - diluted |
Loading...
